Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Keep up to date with all the latest news with our monthly newsletter